A listing of Lancaster General Health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer.This study is Enrolling by Invitation only at Lancaster General Health - ABBCI.
This study compares the impact of using a combination of drugs, ramucirumab and pembrolizumab, versus standard chemotherapy for treating advanced non-small cell lung cancer that is stage IV or recurrent. Ramucirumab blocks new blood vessel growth that tumors need, while pembrolizumab boosts the immune system to fight cancer. The trial …
This study will compare the good and bad effects of not giving regional radiotherapy versus using regional radiotherapy in patients with low risk breast cancer as indicated by Oncotype DX Recurrence Score. This is intended to help researchers discover if not giving regional radiotherapy will be as beneficial as using …
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer …
This post-market registry serves as an ongoing source of product performance, patient safety, and clinical outcomes for a variety of different products. The research design allows products to be added once they are released on the market. Patients are enrolled and followed according to their care provider’s normal care routine.
The OPTIMIZER® INTEGRA CCM-D System, also known as a “Cardiac Contractility Modulation – Defibrillator” is an investigational device system that combines CCM® therapy and ICD therapy into one device. CCM therapy has been shown to improve heart failure symptoms. This clinical trial is designed to determine if the OPTIMIZER® INTEGRA …
The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or temporary stroke-like symptoms when given in addition to standard antiplatelet therapy. The study treatment asundexian is a new type of anticoagulant …
The REAL AF Registry is an observational, prospective, non-randomized registry designed to find out more about the outcomes for patients who receive an ablation as treatment for Paroxysmal Atrial Fibrillation (PAF) and Persistent (PsAF) Atrial Fibrillation. The registry aims to better understand real-world information for patients with this disorder. Eligible …